Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -36.10% is 489% below its 5-year average of -6.13%, around the middle of its 5-year range (-135.11%–45.23%).
52.83% above its 12-month average of -76.53%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -135.11%.
EBITDA MARGIN
-36.10%
EBITDA MARGIN AVG TTM
-76.53%
EBITDA MARGIN AVG 3Y
-27.19%
EBITDA MARGIN AVG 5Y
-6.13%
EBITDA MARGIN AVG 10Y
-4.13%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+52.83%
CURRENT VS 3Y AVG
-32.76%
CURRENT VS 5Y AVG
-488.77%
CURRENT VS 10Y AVG
-774.74%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Sensus Healthcare, Inc.
Market Cap
$49.55M
EBITDA Margin
-36.10%
TTM Avg
-76.53%
3Y Avg
-27.19%
5Y Avg
-6.13%
Market Cap
$49.58M
EBITDA Margin
-61570.00%
TTM Avg
-181077.86%
3Y Avg
-90538.93%
5Y Avg
-60359.29%
Market Cap
$49.47M
EBITDA Margin
-11.13%
TTM Avg
-19.55%
3Y Avg
-13.57%
5Y Avg
-11.41%
Market Cap
$49.44M
EBITDA Margin
-30422.22%
TTM Avg
-16673.71%
3Y Avg
-8702.25%
5Y Avg
-6477.94%
Market Cap
$49.37M
EBITDA Margin
-108.45%
TTM Avg
-10676.44%
3Y Avg
-10454.97%
5Y Avg
-429870.64%
Market Cap
$49.21M
EBITDA Margin
-40.79%
TTM Avg
-44.28%
3Y Avg
-63.47%
5Y Avg
-81.32%
Market Cap
$50.57M
EBITDA Margin
-9115.35%
TTM Avg
-8798.34%
3Y Avg
-6751.54%
5Y Avg
-5839.94%
Market Cap
$50.81M
EBITDA Margin
-10794.00%
TTM Avg
-9994.66%
3Y Avg
-8986.60%
5Y Avg
-8678.68%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sensus Healthcare, Inc. (SRTS) | $49.55M | -36.10% | -76.53% | -27.19% | -6.13% |
| INmune Bio, Inc. (INMB)vs › | $49.58M | -61570.00% | -181077.86% | -90538.93% | -60359.29% |
| Precision Optics Corporation, Inc. (POCI)vs › | $49.47M | -11.13% | -19.55% | -13.57% | -11.41% |
| Microbot Medical Inc. (MBOT)vs › | $49.44M | -30422.22% | -16673.71% | -8702.25% | -6477.94% |
| Apollomics, Inc. (APLM)vs › | $49.37M | -108.45% | -10676.44% | -10454.97% | -429870.64% |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $49.77M | N/A | N/A | N/A | N/A |
| TELA Bio, Inc. (TELA)vs › | $49.21M | -40.79% | -44.28% | -63.47% | -81.32% |
| Envoy Medical, Inc. (COCH)vs › | $50.57M | -9115.35% | -8798.34% | -6751.54% | -5839.94% |
| Clene Inc. (CLNN)vs › | $50.81M | -10794.00% | -9994.66% | -8986.60% | -8678.68% |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | N/A | N/A | N/A | N/A |
Gross Margin
36.4%
EBITDA Margin
-36.1%
Operating Margin
-37.5%
Net Margin
-88.5%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -135.11% |
| 2026-03-31 | -125.57% |
| 2025-12-31 | -61.67% |
| 2025-09-30 | -35.88% |
| 2025-06-30 | -24.40% |
| 2025-03-31 | -29.97% |
| 2024-12-31 | 14.24% |
| 2024-09-30 | 18.07% |
| 2024-06-30 | 22.30% |
| 2024-03-31 | 28.18% |
| 2023-12-31 | 45.23% |
| 2023-09-30 | -45.82% |
| 2023-06-30 | -23.06% |
| 2023-03-31 | -83.95% |
| 2022-12-31 | 32.40% |
| 2022-09-30 | 24.82% |
| 2022-06-30 | 38.44% |
| 2022-03-31 | 38.91% |
| 2021-12-31 | 41.92% |
| 2021-09-30 | 5.83% |
| 2021-06-30 | -2.62% |
| 2021-03-31 | -29.54% |
| 2020-12-31 | 9.73% |
| 2020-09-30 | -129.32% |
| 2020-06-30 | -205.16% |
| 2020-03-31 | -207.50% |
| 2019-12-31 | 13.10% |
| 2019-09-30 | -11.49% |
| 2019-06-30 | 2.65% |
| 2019-03-31 | -37.98% |
| 2018-12-31 | 3.24% |
| 2018-09-30 | -3.62% |
| 2018-06-30 | -6.04% |
| 2018-03-31 | -17.03% |
| 2017-12-31 | -4.74% |
| 2017-09-30 | -17.98% |
| 2017-06-30 | -13.45% |
| 2017-03-31 | -34.31% |
| 2016-12-31 | 2.15% |
| 2016-09-30 | 1.20% |
| 2016-06-30 | -7.41% |
| 2016-03-31 | 3.11% |
| 2015-12-31 | 12.75% |
| 2015-09-30 | 0.23% |
| 2015-06-30 | 0.31% |
| 2015-03-31 | -21.12% |
